FREDERIC J. BROWN / AFP on photo shoots
Every 50 years or older can be approved for a second booster dose of Moderna or Pfizer-BioNtech COVID-19. The Food and Drug Administration is expected to approve new booster images without holding a meeting of its independent dietary guidelines.
The development comes amid increasing reports that defense is missing from three shots and a fourth shot will help increase defense. And while BA.2, a higher -flying omicron species continues to spread in the U.S., there is growing concern that it could re -emerge.
“We had a lot of people about four to six months before their third shot,” said Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, supported the move.
“Without omicron protection, more and more now that we are facing BA.2, there is a higher risk of hospitalization and death,” he said.
But some question the design. Medicines work well in protecting people from serious illness. Critics say there is not enough evidence to warrant a new shot and that it provides a strong defense that will last forever.
“From a scientific point of view, we don’t have any solid evidence that giving a second booster dose is the right way to go in the elderly,” Drs. Celine Gounder, is a clinical psychologist and parent and editor at Kaiser Health News.
He cited data from Israel showing a new disease booster would reduce the risk of serious illness, hospitalization and death for people over 60 years of age.
“I don’t think it’s painful,” said Dr. Carlos del Rio, a clinical pathologist at Emory University, told NPR. “But the reality of the benefit against the disease is short -lived and therefore the benefit is small for most people over 50.” He cited Israeli data showing benefits for those 60 years or more.
Officials say it’s important to give people the option of a speed bump. The plan to give it to young people over 60 is designed to make sure the weaker, more people of color who are more likely to have health problems to deal with, also have the choice of a new booster.
But other health professionals say the administration is focusing on getting people to their primary caregivers and primary motivators.
“What worries me is that we’re not going to invest in increasing the coverage of booster doses and primary sources,” Drs. Saad Omer, director of the Yale Institute for Global Health. “These are things that aren’t enough to look at.”
Unlike the previous controls, the FDA is not intended to make the 2nd booster a recommendation for everyone, but an option for those who want it.